Advertisement
Canada markets open in 5 hours 27 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7331
    +0.0007 (+0.10%)
     

  • CRUDE OIL

    84.13
    +0.56 (+0.67%)
     

  • Bitcoin CAD

    87,696.99
    +321.21 (+0.37%)
     

  • CMC Crypto 200

    1,388.29
    -8.24 (-0.59%)
     

  • GOLD FUTURES

    2,358.30
    +15.80 (+0.67%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,766.25
    +198.75 (+1.13%)
     

  • VOLATILITY

    15.50
    +0.13 (+0.85%)
     

  • FTSE

    8,122.61
    +43.75 (+0.54%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Today’s Research Reports on GeneNews Limited, Knight Therapeutics Inc., Revive Therapeutics Ltd. and Fennec Pharmaceuticals Inc.

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / January 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

GeneNews Limited
https://rdinvesting.com/news/?ticker=GEN.TO

Knight Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GUD.TO

Revive Therapeutics Ltd.
https://rdinvesting.com/news/?ticker=RVV.V

Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO

ADVERTISEMENT

GeneNews stock moved 2.78% lower Thursday, to close the day at $0.17. The stock recorded a trading volume of 809,972 shares, which was above its three months average volume of 696,245 shares. In the last year, GeneNews shares have traded in a range of 0.08 - 0.53. The share price has gained 118.75% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.15 is greater than its 200-day moving average of $0.13. Shares of GeneNews have fallen approximately 22.22 percent year-to-date.

Access RDI's GeneNews Limited Research Report at:
https://rdinvesting.com/news/?ticker=GEN.TO

On Thursday, shares in Knight Therapeutics Inc. recorded a trading volume of 285,428 shares, which was above the three months average volume of 207,417 shares. The stock ended the day 1.57% higher at 8.41. The stock is currently trading 23.55% below its 52-week high with a 52-week trading range of 7.51 - 11.00.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.86 is below its 200-day moving average of $8.72. Shares of the company are trading at a Price to Earnings ratio of 67.28. Shares of Knight Therapeutics Inc. have gained approximately 35.03 percent year-to-date.

Access RDI's Knight Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GUD.TO

Revive Therapeutics stock jumped 7.95% Thursday, to close the day at $0.47. The stock recorded a trading volume of 4,247,980 shares, which was above its three months average volume of 961,209 shares. In the last year, Revive Therapeutics shares have traded in a range of 0.11 - 0.51. The share price has gained 352.38% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.29 is greater than its 200-day moving average of $0.21. Shares of Revive Therapeutics have gained approximately 14.46 percent year-to-date.

Access RDI's Revive Therapeutics Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=RVV.V

On Thursday, shares in Fennec Pharmaceuticals recorded a trading volume of 360 shares, which was below the three months average volume of 2,072 shares. The stock ended the day 1.62% higher at 12.57. The share price has gained 419.42% from its 52-week low with a 52-week trading range of 2.42 - 16.23.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $12.08 is greater than its 200-day moving average of $10.87. Shares of Fennec Pharmaceuticals have gained approximately 0.64 percent year-to-date.

Access RDI's Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO

Our Actionable Research on GeneNews Limited (TSX:GEN.TO), Knight Therapeutics Inc. (TSX:GUD.TO), Revive Therapeutics Ltd. (TSXV:RVV.V) and Fennec Pharmaceuticals Inc. (TSX:FRX.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com